Trials / Completed
CompletedNCT01844115
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder
A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 415 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | |
| DRUG | Vilazodone | Viibryd |
Timeline
- Start date
- 2013-04-30
- Primary completion
- 2014-03-31
- Completion
- 2014-03-31
- First posted
- 2013-05-01
- Last updated
- 2019-12-18
- Results posted
- 2019-12-18
Locations
36 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01844115. Inclusion in this directory is not an endorsement.